Showing results (31-40 of 56) with videos related to
Sort By:
Pageof 6
BMJ (Clinical Research Ed.)|June 28, 2003
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsM R Law, N J Wald, J K Morris, et al.The Journal of Biological Chemistry|January 10, 1982
Heparin with two binding sites for antithrombin or platelet factor 4R E Jordan, L V Favreau, E H Braswell, et al.Journal of the American Academy of Dermatology|May 1, 1985
Remission in skin infiltrate of a patient with mycosis fungoides treated with cyclosporineA M Maddox, B D Kahan, S Tucker, et al.Archives of Dermatology|February 1, 1975
Livedo vasculitis (the vasculitis of atrophie blanche). Immunohistopathologic studyA L Schroeter, J L Diaz-Perez, R K Winkelmann, et al.British Journal of Pharmacology|December 1, 1998
Activation of the cloned human NK3 receptor in Chinese Hamster Ovary cells characterized by the cellular acidification response using the Cytosensor microphysiometerR E Jordan, D Smart, P Grimson, et al.Advances in Experimental Medicine and Biology|January 1, 1977
Studies on lysyl oxidase of bovine ligamentum nuchae and bovine aortaR E Jordan, P Milbury, K A Sullivan, et al.The Journal of Biological Chemistry|June 25, 1989
Inactivation of human antithrombin by neutrophil elastase. Kinetics of the heparin-dependent reactionR E Jordan, R M Nelson, J Kilpatrick, et al.American Heart Journal|March 31, 2000
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximabM A Mascelli, N S Kleiman, S J Marciniak, et al.Hepatology (Baltimore, Md.)|May 1, 1985
The immunologic diagnosis of chronic active "autoimmune" hepatitis: distinction from systemic lupus erythematosusL E Gurian, T M Rogoff, A J Ware, et al.The American Journal of Medicine|September 11, 1989
Antithrombin inactivation by neutrophil elastase requires heparinR E Jordan, R M Nelson, J Kilpatrick, et al.Pageof 6